A patient with acute macular neuroretinopathy and central retinal vein occlusion

Kiriko Hirooka¹
Wataru Saito¹,²
Kousuke Noda¹,²
Susumu Ishida¹,²
¹Department of Ophthalmology, Hokkaido University Graduate School of Medicine, Sapporo, Japan; ²Department of Ocular Circulation and Metabolism, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Purpose: The precise mechanism causing acute macular neuroretinopathy (AMN) is still unknown. A recent report suggested that choroidal circulation impairment correlates with its pathogenesis. We report a rare case with simultaneous onset of AMN and central retinal vein occlusion (CRVO), which is a retinal circulation disorder.

Methods: Case report.

Results: A 44-year-old woman complained of central visual loss of the left eye for the previous 2 weeks. The patient’s visual acuity was 0.5 in the left eye (OS). Fundoscopic examination revealed a wedge-shaped, dark reddish-brown lesion at the macula, and CRVO-like retinal hemorrhages OS. Fluorescein angiography revealed retinal vasculitis and hypofluorescence corresponding to the macular lesion. The patient’s scanning laser ophthalmoscopy infrared imaging result led to a diagnosis of AMN. Two weeks after corticosteroid pulse therapy, her visual acuity improved to 1.2 OS, with improvement of macular findings and Humphrey perimetry. When the dose of oral corticosteroid was decreased, the AMN lesion worsened, with recurrence of retinal hemorrhages. Visual functions improved again after an increased dose of corticosteroid.

Conclusion: These results suggest that circulatory disorders almost simultaneously occurred in choroidal and retinal vessels, resulting in the onset of both AMN and CRVO.

Keywords: choroidal circulation, optical coherence tomography, retinal circulation, systemic corticosteroid therapy

Introduction

Acute macular neuroretinopathy (AMN) is a rare disease characterized by a wedge-shaped, dark reddish-brown lesion at the macula.¹ Scanning laser ophthalmoscopy (SLO) infrared imaging clearly reveals these lesions as hyporeflectivity, which is a characteristic finding in AMN, and this abnormal finding is present even though AMN lesions are not biomicroscopically evident.² The development of spectral-domain optical coherence tomography (OCT) demonstrated that AMN lesions mainly affect the outer retina and not the inner retina.³ Recently, it was reported that hyper-reflective lesions at the level of the outer plexiform and outer nuclear layers on OCT temporarily appeared despite an intact photoreceptor inner/outer segment junction (IS/OS) in patients with early-stage AMN; thereafter, the IS/OS was affected at the same sites.³ Ischemia in the deep inner retinal capillary vessels was speculated as the cause of these newly discovered early OCT lesions,³ because retinal circulation provides photoreceptors with 10% of their oxygen supply. These results suggest the onset of both inner and outer retinal disorders in AMN.

Approximately 10% of AMN patients appear to be complicated by intraretinal hemorrhages, which are inner retinal disorders.⁴,⁵ However, the relationship between...
most of the retinal hemorrhages spontaneously disappeared with withdrawal of oral contraceptives and no medication. The patient was diagnosed with AMN and CR VO OS and was followed up to be restricted mainly to the superotemporal branch and two nasal branches. Systemic screening comprising serological analysis or antibody titres for infectious diseases, including syphilis; Quantiferon; serum autoantibodies, including antiphospholipid antibody; full blood counts; erythrocyte sedimentation rate; serum lipids; serum and urine glucose; hemoglobin A1c; and endogenous coagulation function revealed no abnormalities in the patient. The patient was diagnosed with AMN and CRVO OS and was followed up with withdrawal of oral contraceptives and no medication.

Two months after the first visit, the area of the macular lesion and BCVA remained almost unchanged, although most of the retinal hemorrhages spontaneously disappeared (Figure 2A), together with the resolution of retinal phlebitis and the leakages from the optic disc on late-phase FA (Figure 2B). After informed consent was obtained, corticosteroids were initially administered as per the following schedule: intravenous methyl-prednisolone (mPSL) at 1,000 mg/day for 3 days, oral PSL at 30 mg/day for 7 days, and intravenous mPSL at 1,000 mg/day for 3 days. Oral PSL (30 mg/day) was then administered and tapered by 10 mg/day every 1 month. The patient’s BCVA improved to 1.2 OS 2 weeks after treatment. The dark reddish-brown lesion had shrunk (Figure 2C), and the SLO dark area was reduced (Figure 2D). Humphrey perimetry showed that the central scotoma had shrunk, with marked improvement of
Clinical Ophthalmology 2013:7

A patient with AMN and CRVO

reddish lesion was faintly observed without a dark area on SLO infrared imaging (Figure 3A and B). Late-phase FA and ICGA showed resolution of the hypofluorescent lesions at the macula (Figure 3C and D). OCT revealed complete recovery of the IS/OS, with partial discontinuity of the cone outer segment tip line (Figure 3E, arrows).

Discussion

In this study, we describe an AMN patient with nonischemic CRVO. The lesions and visual functions improved at an early stage after systemic corticosteroid therapy. To our knowledge, this is the first reported AMN case with CRVO.

AMN with intraretinal hemorrhages was previously reported in six patients, however, the extent of retinal hemorrhage was mild in those cases. Retinal capillary disorders following the incidental complication of systemic hypertension was inferred as the cause of intraretinal hemorrhages associated with AMN. However, our patient had no history of arteriosclerotic diseases, including hypertension.

AMN lesions can show hypofluorescence on FA and ICGA, as observed in the present case. We recently used laser speckle flowgraphy to demonstrate reduced choroidal blood flow velocity at the lesion site during the acute phase.

Figure 2 Photographs of the left eye 2 months after the first visit (A and B) and 2 weeks after corticosteroid pulse therapy (C–F): (A) fundus photograph showing the spontaneous absorption of the retinal hemorrhages, although the area of the macular lesion remained unchanged (arrowheads); (B) on late-phase fluorescein angiography, retinal phlebitis and the leakages from the optic disc resolved; (C) the dark reddish lesion improved; (D) the dark area on scanning laser ophthalmoscopy at the lesion site was reduced; (E) on perimetry, the central scotoma had shrunk (mean deviation value: −3.58dB); (F) on optical coherence tomography, the discontinuity of the photoreceptor inner/outer segment junction (arrows) had improved at the fovea.

Figure 3 Findings in the left eye 60 months after the first visit: (A and B) the dark reddish lesion (A) was faintly observed without a dark area on scanning laser ophthalmoscopy infrared imaging (B); (C and D) on late-phase fluorescein angiography (C) and indocyanine green angiography (D), hypofluorescent lesions corresponding to the acute macular neuroretinopathy lesion almost resolved; (E) optical coherence tomography revealed complete recovery of the inner/outer segment junction with partial discontinuity of the cone outer segment tip line (arrows).

Three months after treatment (during oral PSL administration at 15 mg/day), her BCVA was reduced to 0.6 OS, the macular lesion and MD value (−7.42dB) worsened, and the intraretinal hemorrhages recurred. The patient received an increased oral PSL dose (30 mg/day) and a posterior sub-Tenon injection of triamcinolone acetonide (40 mg) OS. The AMN lesion again improved, with the disappearance of the retinal hemorrhages, and BCVA and MD values increased to 0.9 and −6.08dB, respectively, 6 months after the initial treatment. Thereafter, PSL was tapered by 5 mg/day every 2–3 months and was continued for 18 months.

Sixty months after the first visit, the patient’s BCVA and MD values were 0.8 and −3.88dB, respectively. The dark MD value (−3.58dB) (Figure 2E), and that the discontinuity of the IS/OS at the macula had improved (Figure 2F).
of AMN. In the present case, we could not evaluate choroidal circulation impairment using this technique, because of the patient’s poor fixation. Nevertheless, the hypofluorescent areas observed on FA and ICGA at the lesion site suggest choroidal hypoperfusion in this case, because there were no obvious findings on OCT responsible for blocked fluorescence within the AMN lesion. These observations suggest that choroidal circulation impairment is related to the pathogenesis of AMN. On the other hand, CRVO is caused by circulation disturbances in retinal veins following the stenosis or occlusion of the central retinal vein near the lamina cribrosa from unknown causes. CRVO is associated with diseases causing arteriosclerosis in the elderly, whereas it is thought to be associated with vasculitis in young adults. When an AMN lesion recurred, retinal hemorrhages also appeared again. Therefore, we infer that the onset of both AMN and CRVO in the present case was due to circulatory disturbances that occurred almost simultaneously in both choroidal and retinal vessels. Inflammatory mechanisms are speculated because the patient had CRVO with retinal vasculitis and because the functional and morphological abnormalities improved from the early stage after systemic corticosteroid administration, similar to findings in our recently reported case. However, thrombosis following oral contraceptive use or other causes cannot be excluded, because in a large case series of 588 patients with retinal vein occlusion, six of nine patients aged younger than 35 years were taking oral contraceptive pills. Further studies regarding retinal and choroidal blood flow are needed in AMN patients.

In the literature review, AMN lesions showed no spontaneous improvement in 65% of patients. At present, therapeutic strategies for AMN remain to be established. In this case, the IS/OS improved from the early stage after systemic corticosteroid therapy, and finally completely recovered, as in our recently reported case. Thus, these results suggest the potential efficacy of systemic corticosteroid therapy for some AMN patients, and warrant future prospective studies to examine this intervention.

Conclusion

We reported a case of AMN with CRVO. The results suggest that circulatory disorders in the retina and/or choroid relate to the etiology of AMN.

Disclosure

The authors report no conflicts of interest in relation to this work.

References

1. Bos PJ, Deutman AF. Acute macular neuroretinopathy. Am J Ophthalmol. 1975;80(4):573–584.
2. Neuhann IM, Inhoffen W, Koerner S, Bartz-Schmidt KU, Gelisken F. Visualization and follow-up of acute macular neuroretinopathy with the Spectralis® HRA+OCT device. Graefes Arch Clin Exp Ophthalmol. 2010;248(7):1041–1044.
3. Pawzi AA, Pappuru RR, Sarraf D, et al. Acute macular neuroretinopathy: long-term insights revealed by multimodal imaging. Retina. 2012;32(8):1500–1513.
4. Prulick IA, Buettner H, Robertson DM. Acute macular neuroretinopathy. Am J Ophthalmol. 1978;86(6):775–778.
5. Gillies M, Sarks J, Dunlop C, Mitchell P. Traumatic retinopathy resembling acute macular neuroretinopathy. Aust N Z J Ophthalmol. 1997;25(3):207–210.
6. Hashimoto Y, Saito W, Mori S, Saito M, Ishida S. Increased macular choroidal blood flow velocity during systemic corticosteroid therapy in a patient with acute macular neuroretinopathy. Clin Ophthalmol. 2012;6:1645–1649.
7. Yoshizawa C, Saito W, Kase M, Ishida S. Clinical features of central retinal vein occlusion with inflammatory etiology. Asia Pac J Ophthalmol. 2012;1(5):270–276.
8. The Eye Disease Control Study Group. Risk factor for central retinal vein occlusion. Arch Ophthalmol. 1996;114(5):545–554.
9. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921.
10. Kirwan JF, Tsaloumas MD, Vinall H, Prior P, Kritzinger EE, Dodson PM. Sex hormone preparations and retinal vein occlusion. Surv Ophthalmol. 2003;48(1):1–11.